Literature DB >> 30032415

Coronary sinus flow is reduced in methamphetamine abusers: a transthoracic echocardiographic study.

Guang-Liang Wei1, Xiao-Zhi Zheng2, Ke-Qi Chen2, Yun-Yan Shi2, Lian-You Wang3, Xu-Yan Tan4.   

Abstract

To compare the coronary sinus flow among healthy participants, methamphetamine abusers without chest pain and those with chest pain. One hundred and eight methamphetamine abusers: 53 ones without chest pain, 55 ones with chest pain, free of ascertained coronary artery disease, were enrolled in this study. A control group of 50 age-matched male healthy participants was studied for comparison. Standard 2D, flow and tissue Doppler echo with measurements of cardiac morphologic and functional indicators, coronary sinus flow, and inferior vena cava (IVC) ultrasound with measurements of the IVC dimensions and their collapsibility index were performed, respectively. Compared to healthy participants, methamphetamine abusers had higher blood pressure, greater left ventricular mass index and more impaired diastolic function, with preserved cardiac sizes, systolic function and right atrial pressure. Methamphetamine abusers with chest pain had faster heart rate than those without chest pain and healthy participants. Coronary sinus flow was significantly less in methamphetamine abusers than in healthy participants (P < 0.05), and was extremely lower in those with chest pain than in healthy participants (about one-fourth) (P < 0.01). The area under the curve (AUC) of coronary sinus flow was 0.913 (0.864-0.962), and the cutoff value with 221.65 mL/min had sensitivity of 83.4%, specificity of 87.2% and accuracy of 85.2% for differentiating methamphetamine abusers from healthy participants. While the AUC of coronary sinus flow was 0.996 (0.989-1.003), and the cutoff value with 172.59 mL/min had sensitivity of 100%, specificity of 93.3% and accuracy of 96.5% for predicting methamphetamine abusers with chest pain. Coronary sinus flow is significant reduced in methamphetamine abusers, which is maybe a good indicator for indentifying methamphetamine abusers from normal population, and for predicting methamphetamine abusers with chest pain.

Entities:  

Keywords:  Chest pain; Coronary sinus flow; Methamphetamine; Myocardial perfusion; Transthoratic echocardiography

Mesh:

Substances:

Year:  2018        PMID: 30032415     DOI: 10.1007/s10554-018-1417-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  17 in total

Review 1.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 2.  The anatomy of the coronary sinus venous system for the cardiac electrophysiologist.

Authors:  Ammar Habib; Nirusha Lachman; Kevin N Christensen; Samuel J Asirvatham
Journal:  Europace       Date:  2009-11       Impact factor: 5.214

3.  Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey.

Authors:  A I Qureshi; M F Suri; L R Guterman; L N Hopkins
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

4.  Reduced antegrade flow in the coronary sinus is a predictor of coronary artery stenosis in hypertensive patients.

Authors:  Xiaozhi Zheng; Ping Ji; Hongwei Mao; Jianqun Hu
Journal:  J Ultrasound Med       Date:  2012-01       Impact factor: 2.153

5.  Effects of coronary stenoses on coronary flow reserve and resistance.

Authors:  K L Gould; K Lipscomb
Journal:  Am J Cardiol       Date:  1974-07       Impact factor: 2.778

Review 6.  Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.

Authors:  Daniel Ciccarone
Journal:  Prim Care       Date:  2011-01-11       Impact factor: 2.907

7.  Effects of the intracoronary infusion of cocaine on coronary arterial dimensions and blood flow in humans.

Authors:  W C Daniel; R A Lange; C Landau; J E Willard; L D Hillis
Journal:  Am J Cardiol       Date:  1996-08-01       Impact factor: 2.778

8.  Myocardial protection via the coronary sinus.

Authors:  Werner Mohl; Kazuo Komamura; Hirofumi Kasahara; Georg Heinze; Dietmar Glogar; Atsushi Hirayama; Kazuhisa Kodama
Journal:  Circ J       Date:  2008-04       Impact factor: 2.993

9.  Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade.

Authors:  R A Lange; R G Cigarroa; E D Flores; W McBride; A S Kim; P J Wells; J B Bedotto; R S Danziger; L D Hillis
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

10.  Sex-specific assessment of reduced coronary sinus flow in non-hypertensive patients with coronary artery disease at rest.

Authors:  Xiao-Zhi Zheng; Bin Yang; Jing Wu
Journal:  Libyan J Med       Date:  2013-07-16       Impact factor: 1.743

View more
  4 in total

1.  The emergence of cardiac changes following the self-administration of methamphetamine.

Authors:  Jessica L Freeling; Lisa M McFadden
Journal:  Drug Alcohol Depend       Date:  2020-04-23       Impact factor: 4.492

2.  Retinal hypoxia and angiogenesis with methamphetamine.

Authors:  Minsup Lee; Wendy Leskova; Randa S Eshaq; Norman R Harris
Journal:  Exp Eye Res       Date:  2021-03-15       Impact factor: 3.467

Review 3.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

4.  Quality of Life in Patients With Methamphetamine Use Disorder: Relationship to Impulsivity and Drug Use Characteristics.

Authors:  Yingying Wang; Jinsong Zuo; Wei Hao; Hongxian Shen; Xiaojie Zhang; Qijian Deng; Mengqi Liu; Zhiqiang Zhao; Lina Zhang; Yanan Zhou; Manyun Li; Tieqiao Liu; Xiangyang Zhang
Journal:  Front Psychiatry       Date:  2020-09-30       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.